반응식
CS([O:5][CH:6]1[CH2:9][N:8]([C:10]2[N:19]=[CH:18][C:17]([C:20]([F:23])([F:22])[F:21])=[CH:16][C:11]=2[C:12]([O:14]C)=[O:13])[CH2:7]1)(=O)=O.[F:24][C:25]1[CH:30]=[CH:29][C:28](O)=[CH:27][C:26]=1[C:32]([F:35])([F:34])[F:33]>>[F:24][C:25]1[CH:30]=[CH:29][C:28]([O:5][CH:6]2[CH2:9][N:8]([C:10]3[N:19]=[CH:18][C:17]([C:20]([F:23])([F:22])[F:21])=[CH:16][C:11]=3[C:12]([OH:14])=[O:13])[CH2:7]2)=[CH:27][C:26]=1[C:32]([F:33])([F:34])[F:35]참가 물질
3
실험 절차
The title compound (D125) (108 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 4-Fluoro-3-(trifluoromethyl)phenol (60.98 mg, 0.338 mmol).
출처 및 근거
- ORD 기록
- ord-79e437b0e96046e6aff8e2a56f024a1e
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08828987B2
연결된 노트
불러오는 중…